Faeth Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Faeth Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $98.00K.
- Faeth Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $1.03M.
- Faeth Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $2.00K.
- Faeth Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $0.00.
- Faeth Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $2.00K.
- Faeth Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $0.00.
- Faeth Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Faeth Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $238.00K, a 750.00% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $98.00K 10-Q · filed 2026-08-04 | $1.13M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $1.03M 10-Q · filed 2026-08-04 | $1.03M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-15 | |
| 2024-12-31 | $0.00 10-K · filed 2026-03-30 | |
| 2023-12-31 | $0.00 10-K · filed 2025-03-28 | |
| 2022-12-31 | $238.00K 10-K · filed 2024-02-29 | |
| 2022-03-31 | $237.00K 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $28.00K 10-K · filed 2023-03-29 | |
| 2021-03-31 | $1.00K 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $15.00K 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |